Patents by Inventor Karl M. Johnson

Karl M. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240165409
    Abstract: The present disclosure generally relates to auditory nerve stimulation to create the perception of sound in the brain of a subject such as an animal or human being. In one form, a system includes an implantable electrode array including a plurality of spaced apart micro-needles. The system also includes a first electrical lead electrically coupled to and extending from the implantable electrode array, and an auditory signal device configured to produce one or more electrical signals representative of communications received from an external processor. An interposer is configured to electrically couple the implantable electrode array and the auditory signal device in an arrangement where one or more electrical signals produced by the auditory signal device may be transmitted through the first electrical lead to the implantable electrode array. Various novel stimulation strategies can be employed, such as place modulated stimulation signals.
    Type: Application
    Filed: September 18, 2023
    Publication date: May 23, 2024
    Inventors: Moritz Michael Leber, Robert Kyle Franklin, IV, Sandeep Negi, Joseph David Crew, Janet Liu, Vinh Quang Ngo, Hubert Hyoungil Lim, Geoffrey Mohon Ghose, Luke Aaron Johnson, Inderbir Singh Sondh, Abigail Paige Heiller, Meredith Evelyn Adams, Andrew John Oxenham, Thomas Heinrich Robert Lenarz, Karl-Heinz Hiro Dyballa, Waldo Nogueira Vazquez, Amir Samii, Keno H. B. Hübner, Paul Pontiller, Marco Eder, Daniel M. Sieber, Alexander Mayr, Guntram Wyzisk, Elisabeth A. Hansen, Dominik Hammerer, Florian Solzbacher, Loren Wellington Rieth
  • Patent number: 6040298
    Abstract: The present invention relates to pharmaceutical compositions useful for the treatment of subjects suffering from an infection or disease caused by herpes virus strains that are resistant to treatment with acyclovir. In particular, it has been discovered that the low dosage amounts of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU) are effective in inhibiting replication of acyclovir-resistant HSV strains. The present invention is also directed to methods of the preparation of pharmaceutical antiviral compositions and to the methods of their use in the treatment of infection or disease.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: March 21, 2000
    Assignee: Oclassen Pharmaceuticals, Inc.
    Inventors: Dennis W. Adair, Karl M. Johnson, Earl R. Kern